Komori
Other Disclosures1375YUKIGUNI FACTORY CO.,LTD.Food

Research findings on the effects of maitake mushrooms on cognitive function published in the academic journal “Journal of Nutritional Science and Vitaminology”

Findings from a joint study were published in an academic journal, indicating that healthy older adults who consumed the maitake Y10M strain for 18 weeks may have experienced improved cognitive function compared with those who did not consume it. The study also confirmed a correlation between activation of NK cells and improved cognitive function for the Y10M strain, while no significant changes were observed for the C5304 strain.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
18
Weekly
Wording
Avoiding a definitive answer
How definitive the wording is.

Announced details

Maitake (Grifola frondosa) Y10M strainMaitake C5304 strain
Applicable field (uses covered by this announcement)

Cognitive function, immune function, extension of healthy life expectancy and reduction of dementia risk in healthy older adults

What the company reported numerically
Quantitative Effects

In an 18-week consumption study, the group consuming the maitake Y10M strain showed improved cognitive function compared with the non-consumption group. A correlation was identified between activation of NK cells and improved cognitive function. Figures such as the improvement rate are not disclosed.

Relationship between the counterparty and the company
YUKIGUNI FACTORY CO.,LTD.1375
Relationship with the Company

Joint research partner institutions. Capital and personnel relationships are not disclosed.

CounterpartyKobe Pharmaceutical University, an educational corporationKato Hospital, a social medical corporation

Kobe Pharmaceutical University is an educational corporation, and Kato Hospital is a social medical corporation. The chairpersons are listed as Miyata Kyoko (宮田興子) for Kobe Pharmaceutical University and Kato Setsuji (加藤節司) for Kato Hospital. Other information, including the locations, business activities, capital and years of establishment, is not disclosed.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Journal of Nutritional Science and Vitaminology(Jogi et al. 2026, Volume 72, Issue 2, Pages 163-175)

Announced details
ItemDetails
Names of Products / Services CoveredMaitake (Grifola frondosa) Y10M strain, Maitake C5304 strain
CounterpartyKobe Pharmaceutical University, an educational corporation, Kato Hospital, a social medical corporation
Counterparty overviewKobe Pharmaceutical University is an educational corporation, and Kato Hospital is a social medical corporation. The chairpersons are listed as Miyata Kyoko (宮田興子) for Kobe Pharmaceutical University and Kato Setsuji (加藤節司) for Kato Hospital. Other information, including the locations, business activities, capital and years of establishment, is not disclosed.
Relationship with the CompanyJoint research partner institutions. Capital and personnel relationships are not disclosed.
Applicable areaCognitive function, immune function, extension of healthy life expectancy and reduction of dementia risk in healthy older adults
Quantitative EffectsIn an 18-week consumption study, the group consuming the maitake Y10M strain showed improved cognitive function compared with the non-consumption group. A correlation was identified between activation of NK cells and improved cognitive function. Figures such as the improvement rate are not disclosed.
SourceJournal of Nutritional Science and Vitaminology(Jogi et al. 2026, Volume 72, Issue 2, Pages 163-175)
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Preventing progression from a healthy state or mild cognitive impairment is important for preventing the progression of dementia, and the findings indicated that consuming the maitake Y10M strain may help mitigate age-related cognitive decline through the immune system.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Research findings on the effects of maitake mushrooms on cognitive function published in the academic journal “Journal of Nutritional Science and Vitaminology” | YUKIGUNI FACTORY CO.,LTD. (1375) timely disclosure | Komori